# Effect of Oral 6-bromotryptophan on Safety, Pharmacokinetics and Efficacy in Metabolic Syndrome Individuals

> **NCT05971524** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nordin Hanssen** · enrollment: 36 (estimated)

## Conditions studied

- Metabolic Syndrome
- Diabetes Mellitus

## Interventions

- **DIETARY_SUPPLEMENT:** 6-BT
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT05971524
- **Lead sponsor:** Nordin Hanssen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-04
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05971524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05971524, "Effect of Oral 6-bromotryptophan on Safety, Pharmacokinetics and Efficacy in Metabolic Syndrome Individuals". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05971524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*